Obsidian Therapeutics (OBX) Stock Price, News & Analysis

Company Overview

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins. The platform has been applied to cytokines, gene editors, transcription factors and other biological payloads that may be difficult to control with conventional treatment approaches.

The company has advanced programs in oncology, including OBX-115, an engineered tumor-infiltrating lymphocyte therapy designed to support T-cell activity through regulated expression of membrane-bound interleukin-15. Obsidian Therapeutics is based in the United States and has operated as a privately held biotechnology company; reliable information confirming a Nasdaq listing under the symbol OBX was not available.

Key Stats

• Today's Range: $15.85 to $18.11
• 50-Day Range: N/A
• 52-Week Range: $14.57 to $49.97
• Volume: 260,517 shs
• Average Volume: 147,156 shs
• Market Capitalization: $1.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.50
• Consensus Rating: Moderate Buy

Obsidian Therapeutics Stock Analysis - MarketRank™

Obsidian Therapeutics scored higher than 64% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Obsidian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Obsidian Therapeutics has a consensus price target of $42.50, representing about 160.7% upside from its current price of $16.30.

Amount of Analyst Coverage

Obsidian Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Obsidian Therapeutics are expected to decrease in the coming year, from ($1.00) to ($2.99) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.06% of the float of Obsidian Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Obsidian Therapeutics has a short interest ratio ("days to cover") of 0.77, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Obsidian Therapeutics has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Obsidian Therapeutics does not currently pay a dividend.

Dividend Growth

Obsidian Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.44

News Sentiment

Obsidian Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Obsidian Therapeutics this week, compared to 6 articles on an average week.

Search Interest

2 people have searched for OBX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Obsidian Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Obsidian Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Obsidian Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Today: 8/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OBX
• CIK: 2130606
• Web: www.obsidiantx.com
• Phone: N/A
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Obsidian Therapeutics: $42.50
• High Price Target: $43.00
• Low Price Target: $42.00
• Potential Upside/Downside: +160.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 61,770,000
• Free Float: N/A
• Market Cap: $1.01 billion
• Optionable: N/A
• Beta: N/A